Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis

BACKGROUND AND OBJECTIVE: Pirfenidone is an oral antifibrotic agent that is approved in several countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a comprehensive analysis of safety across four clinical trials evaluating pirfenidone in patients with IPF. METHODS: All pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Valeyre, Dominique, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, King, Talmadge E, Leff, Jonathan A, Noble, Paul W, Sahn, Steven A, du Bois, Roland M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230393/
https://www.ncbi.nlm.nih.gov/pubmed/24836849
http://dx.doi.org/10.1111/resp.12297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230393/
https://www.ncbi.nlm.nih.gov/pubmed/24836849
http://dx.doi.org/10.1111/resp.12297

Ejemplares similares